Foghorn Therapeutics Management
Management criteria checks 3/4
Foghorn Therapeutics' CEO is Adrian H. Gottschalk, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $2.50M, comprised of 23.1% salary and 76.9% bonuses, including company stock and options. directly owns 0.92% of the company’s shares, worth $4.25M. The average tenure of the management team and the board of directors is 1.2 years and 7.3 years respectively.
Key information
Adrian H. Gottschalk
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 23.1% |
| CEO tenure | 7.5yrs |
| CEO ownership | 0.9% |
| Management average tenure | 1.2yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk
Oct 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up
Sep 01Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking
Jul 17Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 09Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$86m |
| Mar 31 2024 | n/a | n/a | -US$93m |
| Dec 31 2023 | US$3m | US$579k | -US$98m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$115m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$5m | US$575k | -US$109m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$105m |
| Dec 31 2021 | US$4m | US$540k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$93m |
| Jun 30 2021 | n/a | n/a | -US$85m |
| Mar 31 2021 | n/a | n/a | -US$78m |
| Dec 31 2020 | US$3m | US$479k | -US$69m |
| Sep 30 2020 | n/a | n/a | -US$63m |
| Jun 30 2020 | n/a | n/a | -US$58m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$1m | US$465k | -US$51m |
Compensation vs Market: Adrian H.'s total compensation ($USD2.50M) is about average for companies of similar size in the US market ($USD2.42M).
Compensation vs Earnings: Adrian H.'s compensation has been consistent with company performance over the past year.
CEO
Adrian H. Gottschalk (48 yo)
7.5yrs
Tenure
US$2,503,942
Compensation
Mr. Adrian H. B. Gottschalk serves as President, Chief Executive Officer and a Director of Foghorn Therapeutics Inc. since May, 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Bioge...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.5yrs | US$2.50m | 0.92% $ 4.2m | |
| Chief Scientific Officer | 2.8yrs | US$1.19m | 0.27% $ 1.3m | |
| Chief Medical Officer | 1.2yrs | US$1.84m | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Legal Officer | 4yrs | US$1.99m | 0% $ 0 | |
| Vice President of Corporate Development | 2.8yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief of Staff to the CEO | less than a year | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| VP & Chief of Staff Research | less than a year | no data | no data |
1.2yrs
Average Tenure
52yo
Average Age
Experienced Management: FHTX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.5yrs | US$2.50m | 0.92% $ 4.2m | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | US$157.65k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$159.07k | 0.062% $ 282.7k | |
| Founder & Independent Chairman of the Board | 9.1yrs | US$184.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.3yrs | US$153.07k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$154.57k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$145.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2.2yrs | US$252.52k | 6.55% $ 30.1m |
7.3yrs
Average Tenure
65yo
Average Age
Experienced Board: FHTX's board of directors are considered experienced (7.3 years average tenure).